Quorum Innovations: What We Do.
Novel disease target: impaired barriers.
Environmental exposures break down protective body barriers. Breached barriers including the skin, intestinal tract and mucosal linings of the body result in common and difficult-to-treat diseases.
Quorum Innovations
(“QI”) is the only biotech company in the world
developing microbial biofilms to repair impaired barriers.
QI Biofilm Barrier Protectants are breakthrough
treatments for common conditions like bacterial vaginosis
(BV) and chronic wounds & the orphan disease,
eosinophilic esophagitis (EOE).
Novel therapeutics: Barrier protection is what Quorum Innovations does. Quorum Innovations is the only biotech company in the world developing novel microbiome-based therapeutics to protect and repair impaired barriers. QI Biofilm Barrier Protectants are breakthrough treatments for common conditions like bacterial vaginosis (BV),chronic wounds and the orphan disease, eosinophilic esophagitis (EOE).
Meet our leadership team
Nicholas T. Monsul, MD.
Co-CEO & Co-Founder
Eva Berkes, MD
Co-CEO, CSO & Co-Founder
Jim Self, MBA
CBO
Chris Gardner
Director, R & D
David Whitwell, CPA, MBA
CFO
David Salinwanchik, JD
Patent Attorney/ Advisor
Ankur Ghandi
Regulatory Strategy/Product Development
Katie MacFarlane, PharmD
Market Expert / Advisor
David W. Andrews, M.D.
Co-Founder, Chief Medical Officer
Mark A. Exley, Ph.D.
Chief Scientific Officer
Sean P. Hemingway
Chief Operating Officer
Mark A. Exley, Ph.D.
Chief Scientific Officer
Sean P. Hemingway
Chief Operating Officer
Corporate Presentation
View our corporate presentation at the link below
Corporate Infographic
View our corporate infographic at the link below